Posted by Michael Wonder on 15 Jan 2026
Ontario pioneers access to treatment for severe alopecia areata with Lilly's Olumiant
14 January 2026 - Eli Lilly Canada announced today that Ontario leads the way as the first province to add Olumiant for severe alopecia areata to its public drug formulary--the first and only treatment for adult patients with severe alopecia areata available through public coverage.
On 2 October 2024, Canada's Drug Agency- L'Agence des medicaments du Canada issued a positive final recommendation of reimbursement with conditions for Olumiant as a first-line advanced therapy, recognising the clinical benefit that Olumiant could bring to patients living with severe alopecia areata across Canada.
